Innoen Empagliflozin 10 mg
Empagliflozin 10mg
Tablet · Prescription medication
HK inno.N Co., Ltd.
MFDS item code 202105731 · Approved 2021.08.04
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used to improve blood sugar control in adults with type 2 diabetes. It can be administered alone or in combination with other medications along with dietary therapy and exercise. It is also used in patients with type 2 diabetes who have cardiovascular disease and insufficient blood sugar control; in this case, it is important to consult a specialist and refer to clinical trial information. This medication effectively helps diabetes treatment by managing blood sugar.
The recommended dose of this medicine is 10 mg once daily, both as monotherapy and as add-on combination therapy with other blood glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Elderly patients No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of treatment with this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).
This medication should not be given to certain patients. For example, individuals with allergies to the active ingredient or components of this medication should not take it. Additionally, it is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis. Patients with severely impaired kidney function, such as those with a glomerular filtration rate below 30 mL/min/1.73m2 or those with end-stage renal disease or on dialysis should not take this medication. This medication contains lactose; patients with genetic issues such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should not take it. Careful administration is required for patients with slightly impaired kidney function, and treatment initiation should be avoided in those with a glomerular filtration rate below 60 mL/min/1.73m2, and dosage adjustments or discontinuation may be necessary. Caution is needed for patients with heart failure in NYHA class I-II, and it is not recommended for those in class III-IV. When used with insulin or sulfonylureas, there is a risk of hypoglycemia, so dosage adjustments may be necessary. Common side effects reported include hypoglycemia, genital infections (vulvovaginal candidiasis, vulvitis, glans inflammation, etc.), urinary tract infections, increased urination, decreased body fluid volume, skin rash, and urticaria. Particularly, serious metabolic acidosis such as ketoacidosis may occur, and if symptoms like nausea, vomiting, abdominal pain, or difficulty breathing arise, immediate consultation with medical personnel is necessary. Care is required for the elderly or patients at risk of fluid loss due to potential hypotension or dehydration. This medication may have a slight impact on driving or operating machinery; especially those at risk of hypoglycemia should be cautious. Use is not recommended for pregnant women; if pregnancy is confirmed, treatment should be discontinued. Breastfeeding should be stopped if this medication is taken while nursing. The safety and efficacy in pediatric patients under 18 years have not been established. No specific toxic symptoms have been reported in the case of overdose, but appropriate treatment according to clinical condition is necessary. This medication should be kept out of reach of children and should not be transferred to other containers. Finally, this medication may interact with other drugs, so it is important to consult with healthcare professionals, especially when used in combination with diuretics, insulin, or sulfonylureas.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a closed container to protect it from air or moisture. The storage temperature should be maintained between 1 and 30 degrees Celsius.
Pale yellow round film-coated tablets
30 tablets - 30 tablets/PTP [(10 tablets/PTP×3)], 10 tablets - 10 tablets/PTP [(10 tablets/PTP×1)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 10mg
Tablet · Prescription medication
HK inno.N Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.